GYRE
GYRE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$7.55
+5.15%Next report
Analyst consensus
- Next report date
- Nov 6, 2026
- EPS estimate
- -$0.15
- Revenue estimate
- $28.4M
Latest reported
- Last report date
- Aug 7, 2026
- EPS actual
- -$0.12
- EPS estimate
- -$0.06
- Revenue actual
- $29.1M
- Revenue estimate
- $26.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -26.1%
- Revenue beats (12Q)
- 3
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 7, 2026 | -$0.06 | -$0.12 | Miss -111.75% | $29.1M |
| May 7, 2026 | -$0.06 | -$0.05 | Beat 16.67% | $22.5M |
| Mar 12, 2026 | $0.06 | $0.04 | Miss -29.42% | $37.2M |
| Nov 7, 2025 | $0.05 | $0.06 | Beat 20.00% | $30.6M |
| May 9, 2025 | $0.03 | $0.03 | In line | $22.1M |
| Mar 17, 2025 | $0.04 | $0.01 | Miss -75.00% | $27.9M |
| Nov 13, 2024 | — | $0.02 | — | $25.5M |
| May 9, 2024 | — | $0.04 | — | $27.2M |
| Oct 26, 2023 | -$0.75 | -$1.05 | Miss -40.00% | $30.7M |
| Aug 14, 2023 | -$0.07 | -$0.07 | In line | $26.1M |
| May 15, 2023 | -$1.05 | $0.14 | Beat 113.47% | $24.4M |
| Nov 14, 2022 | -$1.50 | -$0.05 | Beat 96.35% | $29.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 6, 2026